BriaCell Therapeutics Corp.
BCTXNASDAQHealthcare● Active
$3.09
+$0.01(+0.32%)
Market Cap$5820760
P/E Ratio—
52W High$36
52W Low$2.98
BriaCell Therapeutics Corp. (BCTX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BCTX · earnings · updated Jun 8, 2026
Latest Earnings
Q1 FY2026Report Date: Mar 10, 2026EPS Actual
-$2.58
Est. -$4.84 · +46.7%
Revenue
—
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Mar 10, 2026
After Market Close
▲ Beat EPS✓ 3-Quarter EPS Beat Streak
BCTX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▲ Q1 FY2026 | Mar 10, 2026 | -$4.84 | -$2.58 | +46.7% | — | — | — |
| — Q4 FY2025 | Dec 11, 2025 | — | -$4.35 | — | — | — | — |
| ▲ Q4 FY2025 | Oct 27, 2025 | -$12.11 | -$10.49 | +13.4% | — | — | — |
| ▲ Q2 FY2025 | Jun 16, 2025 | -$17.60 | -$16.40 | +6.8% | — | — | — |
| ▼ Q1 FY2025 | Mar 12, 2025 | -$19.40 | -$23.30 | -20.1% | — | — | — |
| ▼ Q4 FY2024 | Dec 16, 2024 | -$0.30 | -$32.98 | -10893.3% | — | — | — |
| — Q3 FY2024 | Jul 31, 2024 | — | -$0.73 | — | — | — | — |
| ▲ Q2 FY2024 | Jun 14, 2024 | -$82.46 | $16.49 | +120.0% | — | — | — |
Q1 FY2026
Mar 10, 2026Beat
EPS Actual
-$2.58
EPS Est.
-$4.84
EPS Surpr.
+46.7%
Revenue
—
Q4 FY2025
Dec 11, 2025
EPS Actual
-$4.35
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2025
Oct 27, 2025Beat
EPS Actual
-$10.49
EPS Est.
-$12.11
EPS Surpr.
+13.4%
Revenue
—
Q2 FY2025
Jun 16, 2025Beat
EPS Actual
-$16.40
EPS Est.
-$17.60
EPS Surpr.
+6.8%
Revenue
—
Q1 FY2025
Mar 12, 2025Miss
EPS Actual
-$23.30
EPS Est.
-$19.40
EPS Surpr.
-20.1%
Revenue
—
Q4 FY2024
Dec 16, 2024Miss
EPS Actual
-$32.98
EPS Est.
-$0.30
EPS Surpr.
-10893.3%
Revenue
—
Q3 FY2024
Jul 31, 2024
EPS Actual
-$0.73
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2024
Jun 14, 2024Beat
EPS Actual
$16.49
EPS Est.
-$82.46
EPS Surpr.
+120.0%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2026 | $-4.84 | $-4.84 | $-4.84 | 1 |
| Q4 FY2025 | $-3.28 | $-3.28 | $-3.28 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q1 FY2026 | Mar 10, 2026 | +46.7% | $3.76 | $3.81 | +1.33% |
| — Q4 FY2025 | Dec 11, 2025 | — | $11.31 | $10.31 | -8.84% |
| ▲ Q4 FY2025 | Oct 27, 2025 | +13.4% | $13.79 | $13.42 | -2.68% |
| ▲ Q2 FY2025 | Jun 16, 2025 | +6.8% | $31.20 | $31.60 | +1.28% |
| ▼ Q1 FY2025 | Mar 12, 2025 | -20.1% | $36.60 | $36.50 | -0.27% |
| ▼ Q4 FY2024 | Dec 16, 2024 | -10893.3% | $99.00 | $91.22 | -7.86% |
| — Q3 FY2024 | Jul 31, 2024 | — | $110.25 | $112.88 | +2.39% |
| ▲ Q2 FY2024 | Jun 14, 2024 | +120.0% | $204.00 | $213.00 | +4.41% |
Q1 FY2026+1.33%
Report Date
Mar 10, 2026
EPS Beat/Miss
+46.7%
Price Before
$3.76
Price After
$3.81
Q4 FY2025-8.84%
Report Date
Dec 11, 2025
EPS Beat/Miss
—
Price Before
$11.31
Price After
$10.31
Q4 FY2025-2.68%
Report Date
Oct 27, 2025
EPS Beat/Miss
+13.4%
Price Before
$13.79
Price After
$13.42
Q2 FY2025+1.28%
Report Date
Jun 16, 2025
EPS Beat/Miss
+6.8%
Price Before
$31.20
Price After
$31.60
Q1 FY2025-0.27%
Report Date
Mar 12, 2025
EPS Beat/Miss
-20.1%
Price Before
$36.60
Price After
$36.50
Q4 FY2024-7.86%
Report Date
Dec 16, 2024
EPS Beat/Miss
-10893.3%
Price Before
$99.00
Price After
$91.22
Q3 FY2024+2.39%
Report Date
Jul 31, 2024
EPS Beat/Miss
—
Price Before
$110.25
Price After
$112.88
Q2 FY2024+4.41%
Report Date
Jun 14, 2024
EPS Beat/Miss
+120.0%
Price Before
$204.00
Price After
$213.00
Avg Beat Reaction+1.08%
Avg Miss Reaction-4.07%
Beat Rate4 / 8 quarters
Largest Move-8.84% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BCTX ends December
BriaCell Therapeutics Corp. (BCTX) most recently reported earnings on March 10, 2026 for Q1 FY2026, posting EPS of $-2.58 — beating the analyst consensus of $-4.84 by +46.7%. BCTX has beaten EPS estimates for 3 consecutive quarters. The next BCTX earnings date is expected around September 1, 2026.
Each quarter, investors track BCTX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BCTX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BCTX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BCTX earnings · 5 questionsBriaCell Therapeutics Corp.'s next earnings report is expected around September 1, 2026. BCTX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BCTX historically reports after market close (AMC).
BCTX earnings datewhen is BCTX earningsBCTX next earnings datewhen does BCTX report earningsBCTX earnings calendar
▸ Source: FMP · BriaCell Therapeutics Corp. SEC filings · US GAAP · BriaCell Therapeutics Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026